Labcorp is proud to offer the broadest blood-based biomarker portfolio for Alzheimer’s disease and dementia

Each of the Alzheimer’s biomarker tests are orderable individually

484390

Phosphorylated Tau 217 (pTau-217), Plasma

An aid in the identification of Alzheimer's disease pathology by detecting the presence or absence of pTau-217, which has been shown in the literature to be a surrogate of amyloid pathology. Additionally, pTau-217 can be used for monitoring patients on newly approved anti-amyloid therapies

505725

Beta Amyloid 42/40 Ratio, Plasma

Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of amyloid pathology for Alzheimer’s disease

484440

Glial Fibrillary Acidic Protein (GFAP)

GFAP is a protein expressed mostly in astrocytes in the brain. In conjunction with markers of amyloid pathology, GFAP has been shown to be a predictor of Alzheimer's disease

140555

Neurofilament Light Chain, Plasma

NfL, in the context of Alzheimer’s disease, provides an indication of disease severity by measuring the current level of neurodegeneration

483745

Phosphorylated Tau 181 (pTau-181), Plasma

This test detects and quantifies pTau-181 proteins in plasma, which has been demonstrated to be predictive in differentiating Alzheimer’s from other dementias

484400

ATN Profile

This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology

Labcorp offers neurological biomarkers for Biopharma

References

  1. Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures
  2. Anderson LA, Day KL, Beard RL, et.al. "The Public's Perceptions About Cognitive Health and Alzheimer's Disease Among the U.S. Population: A National Review". The Gerontologist. 2009; 49(S1): S3-S11.

 Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Multiple Sclerosis

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.

Biomarkers for Drug Development

The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.